Skip to content
Logo APM
  • Login
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
    • Māori
Advanced
  • Real-world effectiveness of pe...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Save to List
  • Permanent link
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study

Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study

Saved in:
Bibliographic Details
Main Authors: Matteo Santoni, Zin Myint, Thomas Büttner, Hideki Takeshita, Y. Okada, Elaine T. Lam, Danielle Gilbert, Zsófia Kürönya, Deniz Tural, Renate Pichler, Enrique Grande, Simon J. Crabb, ROBERT COLEMAN KEMP, Francesco Massari, Sarah Scagliarini, Roberto Iacovelli, Nuno Vau, Umberto Basso, Marco Maruzzo, Javier Molina‐Cerrillo, Luca Galli, Aristotelis Bamias, Ugo De Giorgi, Paolo Andrea Zucali, Mimma Rizzo, Emmanuel Seront, Lazar Popović, Orazio Caffo, Sebastiano Buti, Ravindran Kanesvaran, Jindřich Kopecký, Jakub Kucharz, Annalisa Zeppellini, Ondřej Fiala, Johannes Landmesser, Jawaher Ansari, Patrizia Giannatempo, Alessandro Rizzo, Ignacio Ortego Zabalza, Fernando Sabino Marques Monteiro, Nicola Battelli, Fabio Calabrò, Camillo Porta
Format: Artigo
Language:English
Published: 2023
Online Access:https://doi.org/10.1007/s00262-023-03469-5
Tags: Add Tag
No Tags, Be the first to tag this record!
  • Holdings
  • Description
  • Comments
  • Similar Items
  • Staff View
Be the first to leave a comment!
You must be logged in first

Similar Items

  • Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)
    by: Matteo Santoni, et al.
    Published: (2023)
  • Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de‐differentiation (ARON‐1 study)
    by: Chiara Ciccarese, et al.
    Published: (2024)
  • Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
    by: Francesco Massari, et al.
    Published: (2024)
  • Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
    by: Ondřej Fiala, et al.
    Published: (2023)
  • Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
    by: Camillo Porta, et al.
    Published: (2025)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs

Our networks:

  • Facebook Instagram Linkedin Youtube Spotify Tiktok

Developed by

Logo de acervos digitais